Chinese expert consensus recommendations for the diagnosis and treatment of vitreoretinal lymphoma (2024)

Authors: Ocular Oncology Committee of China Anti-Cancer Association,  Ophthalmological Society of China Medicine Education Association
DOI: 10.3760/cma.j.cn115989-20231204-00195
Published 2024-03-10
Cite as Chin J Exp Ophthalmol, 2024, 42(3): 209-218.

Abstract                              [Download PDF] [Read Full Text]

Vitreoretinal lymphoma (VRL) is a rare and highly aggressive extranodal lymphoma with non-specific clinical features, making it difficult to diagnose and treat consistently.This poses a significant risk to both the patient’s vision and survival that hinders the development of this field.To address this issue, experts from the Ocular Oncology Committee of China Anti-Cancer Association and Ophthalmological Society of China Medicine Education Association have formulated the Chinese expert consensus recommendations for the diagnosis and treatment of vitreoretinal lymphoma (2024) based on the latest research data and consensus recommendations for the disease.The consensus provides opinions on the clinical manifestations, auxiliary examination, diagnosis, differential diagnosis, treatment, and follow-up strategies of VRL, which serve as references for clinicians to improve the diagnosis and treatment level of this disease in China.

Key words:

Vitreoretinal lymphoma; Rules of diagnosis and treatment; Consensus

Contributor Information

Ocular Oncology Committee of China Anti-Cancer Association
Ophthalmological Society of China Medicine Education Association
(Read 10 times, 1 visits today)